SCHEMBL4048126

SCHEMBL4048126

c1ccc(CN2C3CCCCC32)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.53
CHRM2 P08172 1/20 0.52
CHRM4 P08173 1/20 0.52
CHRM5 P08912 1/20 0.52
SIGMAR1 Q99720 1/20 0.48
ACHE P22303 1/20 0.47
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C19 P33261 1/20 0.46
CCR3 P51677 1/20 0.46
HRH3 Q9Y5N1 1/20 0.45
CYP19A1 P11511 1/20 0.45
LMNA P02545 1/20 0.44
DRD2 P14416 1/20 0.43
DRD4 P21917 1/20 0.43
DRD3 P35462 1/20 0.43
OPRL1 P41146 1/20 0.43
NPY1R P25929 1/20 0.43
HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13772148 1.00 ALDH1A1 (0.53) ALDH1A1CHRM2CHRM4CHRM5SIGMAR1
SCHEMBL11913658 0.98 ALDH1A1 (0.52) ALDH1A1CHRM2CHRM4CHRM5SIGMAR1
SCHEMBL10500589 0.95 CHRM2 (0.52) ALDH1A1CHRM2CHRM4CHRM5SIGMAR1
SCHEMBL2933775 0.86 ALDH1A1 (0.52) ALDH1A1CHRM2CHRM4CHRM5SIGMAR1
SCHEMBL1993494 0.85 CHRM2 (0.47) ALDH1A1CHRM2CHRM4CHRM5SIGMAR1
SCHEMBL12830800 0.84 CHRM2 (0.59) ALDH1A1CHRM2CHRM4CHRM5SIGMAR1
Ammonia Solution, Strong SCHEMBL18049528 0.81 CHRM2 (0.56) ALDH1A1CHRM2CHRM4CHRM5HRH3
SCHEMBL4870895 0.80 CHRM2 (0.60) ALDH1A1CHRM2CHRM4CHRM5SIGMAR1
SCHEMBL20483452 0.79 CHRM2 (0.64) ALDH1A1CHRM2CHRM4CHRM5SIGMAR1
SCHEMBL10035310 0.78 ALDH1A1 (0.50) ALDH1A1SIGMAR1ACHENPY1RHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1461315-A4 CATALYTIC CARBONYLATION OF THREE AND FOUR MEMBERED HETEROCYCLES CORNELL RES FOUNDATION INC (US) 2005-06-01 EP claimed
US-6852865-B2 Catalytic carbonylation of three and four membered heterocycles CORNELL RESEARCH FOUNDATION, INC. (US) 2005-02-08 US claimed
EP-1461315-A2 CATALYTIC CARBONYLATION OF THREE AND FOUR MEMBERED HETEROCYCLES CORNELL RESEARCH FOUNDATION, INC. (US) 2004-09-29 EP claimed
US-20030162961-A1 Catalytic carbonylation of three and four membered heterocycles CORNELL RESEARCH FOUNDATION, INC. 2003-08-28 US claimed
WO-2003050154-A2 CATALYTIC CARBONYLATION OF THREE AND FOUR MEMBERED HETEROCYCLES CORNELL RESEARCH FOUNDATION, INC. (US) 2003-06-19 WO claimed
EP-1461315-B1 CATALYTIC CARBONYLATION OF THREE AND FOUR MEMBERED HETEROCYCLES CORNELL RES FOUNDATION INC (US) 2009-07-29 EP disclosed
EP-1461315-A4 CATALYTIC CARBONYLATION OF THREE AND FOUR MEMBERED HETEROCYCLES CORNELL RES FOUNDATION INC (US) 2005-06-01 EP disclosed
US-6852865-B2 Catalytic carbonylation of three and four membered heterocycles CORNELL RESEARCH FOUNDATION, INC. (US) 2005-02-08 US disclosed
EP-1461315-A2 CATALYTIC CARBONYLATION OF THREE AND FOUR MEMBERED HETEROCYCLES CORNELL RESEARCH FOUNDATION, INC. (US) 2004-09-29 EP disclosed
US-20030162961-A1 Catalytic carbonylation of three and four membered heterocycles CORNELL RESEARCH FOUNDATION, INC. 2003-08-28 US disclosed
WO-2003050154-A2 CATALYTIC CARBONYLATION OF THREE AND FOUR MEMBERED HETEROCYCLES CORNELL RESEARCH FOUNDATION, INC. (US) 2003-06-19 WO disclosed
EP-0121972-B1 N-ARYL-ALPHA-AMINO-CARBOXAMIDES JANSSEN PHARMACEUTICA N.V. (BE) 1989-05-24 EP disclosed
EP-0121972-A2 N-aryl-alpha-amino-carboxamides JANSSEN PHARMACEUTICA N.V. (BE) 1984-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162961-A1 Catalytic carbonylation of three and four membered heterocycles LOX, CA9, LPO ALDH1A1 1604/4885CHRM2 294/4885CHRM4 400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.